Pharmaceutically active lipid based formulation of SN-38
AssigneeNeoPharm, Inc.
InventorsImran Ahmad, Jia-Ai Zhang
Life of this patent
Estimating the term…
Loading patent…
AssigneeNeoPharm, Inc.
InventorsImran Ahmad, Jia-Ai Zhang
Estimating the term…
SN38, camptothecin derivatives are poorly water soluble, highly lipophilic camptothecin derivatives and are very active against a variety of human cancers. Because of their very poor water solubility, SN38 has not been used to treat human patients with cancer due to the inability to administer sufficient quantities of dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable SN38 liposome complex formulation for the direct administration of the formulation to human patients with cancer. The claimed invention also describes the methods to prepare liposomal SN38 complexes and antitumor compositions of liposomal SN38 complexes to allow the administration in sufficient amounts to treat various types of cancer and as antiviral agents. This invention is also directed to injectable sterile solutions, antitumor compositions, liposomes. The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN38 into complexes and are capable of solubilizing relatively high concentrations of SN38.
A method of treating viral infections comprising administering to a patient having a viral infection a composition comprising a complex comprising SN38 or a chemical in equilibrium with SN38 and a lipid to the patient in an amount sufficient to treat the viral infection within the patient.
A method of treating pancreatic cancer in a patient comprising administering to a patient having pancreatic cancer a complex comprising SN38 or a chemical in equilibrium with SN38 and a lipid to the patient in an amount sufficient to treat the cancer within the patient.
A method of treating a disease caused by proliferating eukaryotic cells in a patient homozygous for the wild-type UGTA1 allele or having at least one copy of the UGTA1*28 allele comprising administering to a patient having a disease caused by proliferating eukaryotic cells a complex comprising SN38 or a chemical in equilibrium with SN38 and a lipid to the patient in an amount sufficient to treat the disease caused by proliferating eukaryotic cells within the patient, wherein the patient has at least one copy of the UGTA1 allele.
A method of administering a composition comprising a composition selected from SN38 or a chemical in equilibrium with SN38 and a lipid to a human patient, wherein the composition is administered over a period of from about 30 to about 180 minutes.
A method of forming a lipid composition comprising an agent selected from SN38 or a chemical in equilibrium with SN38, involving forming a lipid phase and thereafter hydrating the lipid phase with a first aqueous solution including the compound so as to form lipid composition including the compound, and thereafter reducing the pH of the lipid composition, wherein the pH is reduced to less than 3.5.
Dependencies are inferred from the claim text.